- Raw materials
- Platelet Aggregation Inhibitors
- Dersalazine
Dersalazine API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Dersalazine | CAS No: 188913-58-8 | GMP-certified suppliers
A medication that targets inflammatory bowel disease by modulating inflammatory pathways associated with ulcerative colitis and Crohn’s disease for investigational therapeutic development.
Therapeutic categories
Primary indications
- Investigated for use/treatment in inflammatory bowel disease
Product Snapshot
- Dersalazine is an oral small molecule formulation
- It is primarily investigated for inflammatory bowel disease indications
- The compound is currently in the investigational stage and has not received FDA or EMA approval
Clinical Overview
Pharmacologically, Dersalazine belongs to chemical classes including carbocyclic acids, benzene derivatives, benzoates, hydroxy acids, hydroxybenzoates, and phenols. It falls within drug categories of platelet activating factor (PAF) antagonists and inhibitors, and salicylates, suggesting a multifaceted approach to modulating inflammatory pathways. However, explicit data describing its pharmacodynamics and precise mechanism of action have not been disclosed in the available literature. The classification implies possible involvement in the inhibition of PAF-mediated inflammatory signaling, which is relevant to IBD pathology.
Key absorption, distribution, metabolism, and excretion (ADME) parameters for Dersalazine have not been comprehensively characterized. This includes limited information on bioavailability, metabolic pathways, elimination half-life, and excretion routes, which are essential for clinical dose optimization and safety assessments.
Safety and toxicity profiles remain to be established through ongoing or future clinical investigations. Given its investigational status, comprehensive toxicological data, drug interaction potential, and contraindications have not been fully delineated.
No approved branded formulations of Dersalazine are currently available on the global market. Its status as an experimental agent restricts its use to clinical trials or research settings.
From a sourcing and quality perspective, procurement of Dersalazine active pharmaceutical ingredient (API) should adhere to stringent quality standards, including verification of chemical purity, confirmation of identity via validated analytical methods, and compliance with regulatory guidelines pertinent to investigational compounds. Given the lack of broad commercial availability, suppliers with robust characterization documentation and adherence to Good Manufacturing Practice (GMP) are preferred to ensure reproducibility and regulatory compliance in pharmaceutical development.
Identification & chemistry
| Generic name | Dersalazine |
|---|---|
| Molecule type | Small molecule |
| CAS | 188913-58-8 |
| UNII | WS1IH75AJT |
| DrugBank ID | DB06251 |
Formulation & handling
- Dersalazine is a small molecule with low water solubility, indicating potential formulation challenges for oral bioavailability. Its high logP value suggests lipophilic properties, favoring lipid-based formulations or solubilization strategies. Stable as a solid, proper handling should ensure protection from moisture to maintain product integrity.
Regulatory status
Dersalazine is a type of Platelet Aggregation Inhibitors
Platelet Aggregation Inhibitors are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) used in the field of cardiology and thrombosis management. These inhibitors play a vital role in preventing platelet aggregation, a process responsible for the formation of blood clots. By inhibiting platelet aggregation, these APIs reduce the risk of arterial thrombosis, which can lead to severe cardiovascular events like heart attacks and strokes.
Platelet Aggregation Inhibitors primarily work by targeting specific receptors on platelet cells, thereby impeding their activation and subsequent aggregation. The most commonly utilized APIs in this category include acetylsalicylic acid (aspirin), clopidogrel, ticagrelor, and prasugrel. These drugs are available in various forms, such as tablets, capsules, and intravenous formulations, allowing flexibility in their administration.
The effectiveness of Platelet Aggregation Inhibitors lies in their ability to prevent platelets from adhering to each other and forming clots within blood vessels. This property is especially crucial in patients with a high risk of cardiovascular events, such as those with a history of heart disease, diabetes, or peripheral artery disease.
While Platelet Aggregation Inhibitors are generally safe and effective, they can also carry potential side effects, including bleeding complications. Therefore, their administration requires careful consideration of individual patient characteristics and risk factors.
In conclusion, Platelet Aggregation Inhibitors represent a significant category of pharmaceutical APIs used for the prevention of platelet aggregation and subsequent blood clot formation. By inhibiting this process, they contribute to the management and reduction of cardiovascular events, offering critical benefits to patients at risk.
